Phase 2 to Assess Efficacy and Safety in AR882 Alone or in Combination With Allopurinol in Patients With Tophaceous Gout
Public ClinicalTrials.gov record NCT05253833. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Randomized, Open-Label, Allopurinol-Controlled, Multicenter Study With Two Optional Extensions to Evaluate the Safety and Efficacy of AR882 Alone or in Combination With Allopurinol in Tophaceous Gout Patients
Study identification
- NCT ID
- NCT05253833
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Arthrosi Therapeutics
- Industry
- Enrollment
- 42 participants
Conditions and interventions
Conditions
Interventions
- AR882 Dose 1 Drug
- AR882 Dose 2 Drug
- Allopurinol Tablet Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 11, 2022
- Primary completion
- Aug 12, 2024
- Completion
- Oct 27, 2024
- Last update posted
- Jan 28, 2025
2022 – 2024
United States locations
- U.S. sites
- 10
- U.S. states
- 8
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Arthrosi Investigative Site (410) | Birmingham | Alabama | 35233 | — |
| Arthrosi Investigative Site (403) | Phoenix | Arizona | 85032 | — |
| Arthrosi Investigative Site (416) | Sun City | Arizona | 85351 | — |
| Arthrosi Investigative Site (417) | Tucson | Arizona | 85704 | — |
| Arthrosi Investigative Site (402) | Tampa | Florida | 33606 | — |
| Arthrosi Investigative Site (404) | Boise | Idaho | 83713 | — |
| Arthrosi Investigative Site (409) | Ann Arbor | Michigan | 48109 | — |
| Arthrosi Investigative Site (406) | Greensboro | North Carolina | 27410 | — |
| Arthrosi Investigative Site (408) | Myrtle Beach | South Carolina | 29577 | — |
| Arthrosi Investigative Site (401) | Dallas | Texas | 75231 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 2 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05253833, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 28, 2025 · Synced May 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05253833 live on ClinicalTrials.gov.